Parents of a Child With Fatal Marfan Diagnosis Drove Researchers Toward a New Genetic Strategy: Modifier Genes

A Fatal Prognosis, and a Father on the Floor

When Ludivine Verboogen and Romain Alderweireldt's son was born in Belgium in late 2015, doctors eventually gave them a number: 16 months. That was the expected ceiling on his life, delivered shortly before he turned a year old.

Marfan syndrome involves mutations in a gene that builds connective tissue. The condition is associated with exceptional height, long limbs, and a sharply elevated risk of fatal aortic rupture. Abraham Lincoln is among those believed to have carried it. The neonatal form is the most severe variant, and it almost always kills in infancy.

Romain, upon hearing the diagnosis, lay down on his office floor. His boss found him there and told him to get up and find a solution. That moment became the starting point for a scientific search that researchers are still pursuing today.

The Modifier Gene Hypothesis

Romain and Ludivine came across a published study in which scientists analyzed genetic data from more than 500,000 people and identified 13 adults who were alive and healthy despite carrying mutations that normally cause severe childhood illness. These individuals had not simply gotten lucky. Researchers believed their other genes, so-called modifier genes, were actively counteracting the dangerous mutation.

The hypothesis is straightforward. A harmful mutation in one gene does not operate in a vacuum. Other genes, elsewhere in the genome, may dampen, redirect, or block the downstream effects of the primary mutation. If scientists can identify which modifier genes do this, they have a potential therapeutic target.

Romain looked for equivalent research in Marfan syndrome. There was none.

122 People Who Should Be Sick

So he started looking himself. Combing through publicly available genetic databases, Romain identified 122 people who carry Marfan mutations but show no apparent symptoms of the disease. Twenty-four of them specifically carry errors in the gene associated with the neonatal form, the same mutation his son has.

Catherine Boileau, a geneticist at the French health research institution INSERM, told The Atlantic that Marfan syndrome is unusually inconsistent even within the same family. Two relatives who carry the identical mutation can have completely different health trajectories: one might suffer a fatal aortic tear early in life, the other might reach adulthood with only mild symptoms and never require surgery. That variability is not random noise. It almost certainly reflects genetic architecture elsewhere in the genome.

Boileau's observation points to a crucial narrowing of the target. If the modifier effect were environmental—diet, exercise, random chance—you would not expect to see it clustering within families the way it does. Genetics is the more parsimonious explanation.

Why This Matters Beyond Marfan

The modifier gene framework, if validated, would be broadly applicable. Marfan is a relatively rare condition, but the logic applies to any monogenic disease. Boileau has seen it work before: she was involved in early research into a gene called PCSK9, where mutations that lower the gene's activity can avert sky-high cholesterol levels caused by inherited errors in another gene. That discovery helped create a class of drugs that mimic the effects of disabling PCSK9. Modifier genes have also played a role in sickle cell disease, where one of the very first gene-editing therapies approved by the FDA works precisely by shutting down a modifier gene to prompt cells to produce a backup form of hemoglobin.

Finding a gene that neutralizes a lethal mutation does not require editing the dangerous gene itself. It opens a second door.

That distinction is significant from a regulatory and ethical standpoint. A therapy that amplifies or mimics a naturally occurring modifier gene is working with something the human body has already demonstrated it can tolerate—at least in the people who carry it naturally.

The strongest counterargument is that correlation is not causation. The 122 asymptomatic Marfan mutation carriers Romain identified may lack symptoms for reasons that have nothing to do with modifier genes. They might be younger than the age at which symptoms typically appear. They might have milder alleles. The databases Romain searched rely on self-reported health data and clinical records that may be incomplete. Identifying true modifiers requires rigorous functional studies, not just pattern-matching in population databases. Researchers will need to demonstrate, in cell or animal models, that a candidate modifier gene actually changes disease outcomes when manipulated—a process that takes years.

Boileau and the broader scientific community are aware of this. The 13 "resilient individuals" identified in the original 500,000-person study have been scrutinized for years, and finding actionable modifiers from that cohort has proven harder than the initial finding suggested.

Where the Research Stands

The search for Marfan-specific modifier genes is ongoing. Romain's database of 122 asymptomatic carriers represents a starting point for deeper genomic analysis, not a finish line. INSERM's Boileau is involved in the scientific effort. Meanwhile, the Resilience Project—the initiative that first inspired Romain and Ludivine—is looking to reboot, with plans to apply AI tools to scan more than 2 million genomes for more than 500 rare and ultra-rare diseases.

Romain and Ludivine's son has already outlived his original prognosis. Whether that survival reflects a modifier gene, the specific nature of his mutation, medical management, or some combination of factors is one of the unresolved questions researchers are trying to answer—and the answer could determine whether his case points toward a treatment, or remains a fortunate outlier.